Recent advance in the sensing of biomarker transcription factors

Cancer is a malignant disease that endangers human life, especially owing to its high fatality rate; therefore, rapid and accurate early screening is needed to effectively improve the survival rate. Compared with traditional cancer detection methods, electrochemical biosensors that recognize cancer biomarkers in blood have the advantages of low invasiveness, fast diagnosis, and low cost. However, there is always a trade‐off between sensitivity and selectivity, which limits the detection of trace amounts of biomarkers produced in the early stages. To address this issue, an increasing number of nanomaterials with simultaneous improvements in both sensitivity and selectivity have recently been reported. In this review, different categories of state‐of‐the‐art electrochemical biosensors and their operating principles are introduced, and their respective advantages and disadvantages are described. Furthermore, the review discusses the existing detection strategies and performance of nanomaterial‐based cancer biosensors for biomarker recognition, providing overall guidance for the material selection of different biomarkers. Finally, the main challenges involving existing electrochemical cancer biosensors are evaluated to present the future development prospects of nanomaterials and detection strategies.

show abstract

“…The available objects for detection are labeled proteins, antibodies, DNA sequences, miRNAs, or cancer cells. [ 47 ]…”

Section: Electrochemical Cancer Biosensorsmentioning

confidence: 99%

Recent Progress on Nanomaterial‐Facilitated Electrochemical Strategies for Cancer Diagnosis

Yuan

Lin

Liu

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Transcription factors are currently widely used as diagnostic biomarkers for the early detection of several diseases [211][212][213]. A wide range of brain-related disorders and cancers are accompanied by alterations in the levels and activity of TFAP2Β/AP-2β, which underscores its diagnostic importance for such diseases.…”

Section: Ap-2β As a Biomarkermentioning

confidence: 99%

The regulatory role of AP-2β in monoaminergic neurotransmitter systems: insights on its signalling pathway, linked disorders and theragnostic potential

et al. 2022

View full text Add to dashboard Cite

Monoaminergic neurotransmitter systems play a central role in neuronal function and behaviour. Dysregulation of these systems gives rise to neuropsychiatric and neurodegenerative disorders with high prevalence and societal burden, collectively termed monoamine neurotransmitter disorders (MNDs). Despite extensive research, the transcriptional regulation of monoaminergic neurotransmitter systems is not fully explored. Interestingly, certain drugs that act on these systems have been shown to modulate central levels of the transcription factor AP-2 beta (AP-2β, gene: TFAP2Β). AP-2β regulates multiple key genes within these systems and thereby its levels correlate with monoamine neurotransmitters measures; yet, its signalling pathways are not well understood. Moreover, although dysregulation of TFAP2Β has been associated with MNDs, the underlying mechanisms for these associations remain elusive. In this context, this review addresses AP-2β, considering its basic structural aspects, regulation and signalling pathways in the controlling of monoaminergic neurotransmitter systems, and possible mechanisms underpinning associated MNDS. It also underscores the significance of AP-2β as a potential diagnostic biomarker and its potential and limitations as a therapeutic target for specific MNDs as well as possible pharmaceutical interventions for targeting it. In essence, this review emphasizes the role of AP-2β as a key regulator of the monoaminergic neurotransmitter systems and its importance for understanding the pathogenesis and improving the management of MNDs.

show abstract

“…However, even if microfluidics can help in reagent managing, the development of cartridges or preloading reagents on paper substrates can help to overcome mismanagement by nonexperts. Additionally, new biomolecular techniques such CRISPR/CAS can play a key role in the improvement of selectivity and sensitivity of POCT and even for the detection of innovative biomarkers such as transcription factors …”

Section: Point-of-care Testing: Massive Inexpensive Fast Diagnosismentioning

confidence: 99%

“…Additionally, new biomolecular techniques such CRISPR/CAS can play a key role in the improvement of selectivity and sensitivity of POCT 57 and even for the detection of innovative biomarkers such as transcription factors. 58 ■ ELECTROCHEMICAL SENSORS GO WEARABLE:…”

mentioning

confidence: 99%

Electrochemical Sensing Directions for Next-Generation Healthcare: Trends, Challenges, and Frontiers

2020

View full text Add to dashboard Cite

Recent advance in the sensing of biomarker transcription factors

Cited by 17 publications

References 140 publications

Recent Progress on Nanomaterial‐Facilitated Electrochemical Strategies for Cancer Diagnosis

Recent Progress on Nanomaterial‐Facilitated Electrochemical Strategies for Cancer Diagnosis

The regulatory role of AP-2β in monoaminergic neurotransmitter systems: insights on its signalling pathway, linked disorders and theragnostic potential

Electrochemical Sensing Directions for Next-Generation Healthcare: Trends, Challenges, and Frontiers

Contact Info

Product

Resources

About